Authored By: Adwoa Birago Oware-Mintah
Ghana School of Law
Abstract
Access to medicine lies between law, economics, and public health. Intellectual property rights, especially patents, encourage pharmaceutical innovation by protecting investments in developing new drugs. However, these protections can also make medicines expensive and inaccessible, particularly in developing countries. This article seeks to examine the tension between patent protection and access to medicines, arguing that the relationship is more complex than a simple conflict between profit and welfare. Although international law allows some flexibility, such as compulsory licensing, these measures are often difficult to apply effectively. A better balance is needed to ensure both innovation and access.
Overview of Intellectual Property Rights in Pharmaceuticals
Intellectual property rights, particularly patents, play a central role in the pharmaceutical industry. A patent gives its holder the exclusive right to make, use, or sell an invention for a limited period. In the context of medicines, this allows pharmaceutical companies to control production and pricing without competition. The justification is that developing new drugs is costly and risky, so patent protection enables companies to recover investments and earn profit.[1]
At the international level, the legal framework is largely shaped by the TRIPS Agreement, which sets minimum standards for IP protection across World Trade Organization member states. TRIPS requires countries to provide patent protection for pharmaceuticals, usually for at least 20 years.[2] This has significantly affected developing countries, limiting earlier flexibility. Other bodies, such as the World Intellectual Property Organization and the World Health Organization, also play roles, reflecting the broader tension between protecting innovation and promoting public health.[3]
III. The Right to Health and Access to Medicines
Access to medicines is not just a policy concern; it is part of the broader right to health. Under international human rights law, states must ensure essential healthcare is available and accessible, including necessary medicines.[4]
In practice, this is more complex. Medicines are unevenly distributed, and affordability remains a major barrier, especially in developing countries. Even basic treatments can be too expensive for large segments of the population. This is where intellectual property becomes relevant. Patent protection limits competition and often keeps prices high for longer periods.[5] However, patents are not the only factor. Weak healthcare systems, poor infrastructure, and limited funding also restrict access. International organizations have identified “essential medicines,” but availability does not always mean accessibility. Thus, while the right to health provides a strong framework, its enforcement in the context of patented medicines remains difficult, leaving a gap between legal recognition and actual access.
Conflict Between IP Protection and Public Health
The tension between intellectual property protection and public health is most visible in drug pricing. While patents are intended to reward innovation, they can create monopolies that allow companies to set high prices without competition. This may be manageable in wealthier countries, but in lower-income settings, it often makes essential medicines unaffordable.[6]
This problem has been evident in public health crises. During the HIV/AIDS epidemic, antiretroviral drugs were initially priced beyond the reach of many developing countries until generic alternatives reduced costs.[7] Similar concerns arose during the COVID-19 pandemic, where access to vaccines and treatments was uneven.
These examples show that strict patent protection can conflict with public health needs. Balancing innovation incentives with access to medicines remains a complex and unresolved challenge.
TRIPS Flexibilities and Public Health Safeguards
Although the TRIPS Agreement sets minimum standards for patent protection, it also includes flexibilities that allow states to respond to public health needs. These provisions aim to balance intellectual property rights with access to medicines, though their use is often difficult in practice.[8]
One key mechanism is compulsory licensing, which allows a government to authorize production or importation of a patented medicine without the patent holder’s consent in public health situations. This can improve access by bypassing high prices, but countries may face political or economic pressure when using it.[9]
Another flexibility is parallel importation, which enables importing cheaper versions of patented medicines from other markets. The effectiveness of both tools depends on national laws and external pressures. The Doha Declaration on TRIPS and Public Health clarified that states may priorities public health and access to medicines.[10] However, many developing countries still lack the capacity to fully use these flexibilities, limiting their impact in practice.
VII. Policy and Reform Proposals
Given the limits of the current system, several reform proposals have been suggested. Some focus on adjusting patent rules, while others seek alternatives. There is no single agreed solution, reflecting the complexity of the issue.
One proposal is to tighten patent standards to address practices like evergreening, ensuring that only genuine innovations receive protection. This would prevent minor modifications from extending monopoly rights. Another proposal is to reconsider patent duration, though this is controversial, especially for industry stakeholders.
Alternative models also exist, such as prize funds or public funding for research. These aim to separate the cost of innovation from medicine pricing, making drugs more affordable. However, they raise questions about funding and implementation. Overall, most reforms involve trade-offs between encouraging innovation and improving access. The key challenge is finding a practical and balanced approach.
VIII. Future Challenges
Even beyond current debates, emerging issues may further complicate the balance between intellectual property and access to medicines. One key concern is pandemic preparedness. The COVID-19 experience showed how quickly global demand for vaccines and medicines can rise, and how uneven access can become, especially in lower-income countries.[11]
Another challenge is the rise of complex medical technologies such as biologics and gene therapies. These treatments are more expensive to develop and harder to replicate than traditional drugs, making patents even more significant because generic alternatives are limited. This may worsen access problems.
Global inequality is also a continuing issue. Wealthier countries are generally better positioned to secure access to new treatments, while poorer countries often rely on delayed supply or external support.
Overall, these developments show that the relationship between intellectual property and access to medicines is evolving, and legal responses will need to adapt over time.
Conclusion
The relationship between intellectual property rights and access to medicines is not easy to resolve, and this article has shown why. Patents do play an important role in encouraging innovation, especially in an industry where research is costly and uncertain. But at the same time, they can create barriers that limit access to essential medicines, particularly in developing countries. That tension runs through almost every part of the discussion.
What makes the issue more complicated is that neither side can be ignored. Weakening patent protection t could reduce incentives for developing new drugs. Yet maintaining strict protection without flexibility risks leaving large parts of the global population without access to life-saving treatment. The current framework tries to balance these concerns, but it does not always succeed in practice.
Mechanisms like compulsory licensing and the Doha Declaration show that the law does recognize the need for flexibility. Still, their impact has been uneven, and in some cases, more symbolic than practical. This suggests that legal solutions alone may not be enough. Broader policy changes, including alternative models for funding research and stronger international cooperation, are likely to be necessary.
In the end, the challenge is ongoing. There is no final solution that neatly resolves the conflict between innovation and access. What is required instead is a system that can adapt by providing incentives for innovation while ensuring that medicines are not treated purely as market commodities. Without that balance, the goal of improving global public health will remain difficult to achieve.
Reference(S):
[1] William M Landes and Richard A Posner, The Economic Structure of Intellectual Property Law (Harvard University Press 2003)
[2] Agreement on Trade-Related Aspects of Intellectual Property Rights (1995) (TRIPS Agreement).
[3] Carlos M Correa, Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (Zed Books 2000).
[4] International Covenant on Economic, Social and Cultural Rights (1976) (ICESCR); Committee on Economic, Social and Cultural Rights, ‘General Comment No 14: The Right to the Highest Attainable Standard of Health’
[5] Ellen F M ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power (AMB 2009).
[6] Joseph E Stiglitz, Making Globalization Work (Penguin 2007).
[7] n 5
[8] TRIPS Agreement
[9] Carlos M Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on the TRIPS Agreement
[10] World Trade Organization, Declaration on the TRIPS Agreement and Public Health (2001) (Doha Declaration).
[11] World Health Organization, Global Vaccine Equity: Addressing the Imbalance (WHO 2021).
